search
Back to results

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial (ARCTIC)

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Ultrasonography
Sponsored by
Espen A. Haavardsholm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring rheumatoid arthritis, ultrasonography, remission, imaging remission, tight control, treat to target

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria (all):

  • Male or non-pregnant, non-nursing female
  • > 18 years of age and < 75 years of age
  • Patients classified as having RA (according to new ACR/EULAR criteria)
  • Disease duration less than 2 years (defined as time from 1st joint swelling)
  • The treating rheumatologist decides the patient requires treatment with a Disease Modifying Anti-Rheumatic Drug (DMARD)
  • The patient has taken no prior DMARD
  • Patients able and willing to give written informed consent and comply with the requirements of the study protocol

Exclusion Criteria (any):

  • Abnormal renal function (serum creatinine > 142 µmol/L in female and > 168 µmol/L in male)
  • Abnormal liver function, active or recent hepatitis, cirrhosis
  • Major co-morbidities like severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease and/or severe respiratory diseases.
  • Leukopenia and/or thrombocytopenia
  • Inadequate birth control conception, pregnancy, and/or breastfeeding
  • Indications of active tuberculosis
  • Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible

Sites / Locations

  • Martina Hansens Hospital AS
  • Sykehuset Østfold HF, Dept. of Rheumatology
  • Helse Bergen HF, Haukeland University Hospital, Dept. of Rheumatology
  • Vestre Viken HF, Dept. of Rheumatology
  • Haugesund Sanitetsforening Revmatismesykehus
  • Sørlandet Sykehus HF, Dept. of Rheumatology
  • Revmatologene bendvold/Dovland
  • Diakonhjemmet Sykehus AS, Dept. of Rheumatology
  • Universitetssykehuset Nord-Norge HF, Dept. of Rheumatology
  • St Olavs Hospital HF, Dept. of Rheumatology
  • Helse Sunnmøre HF, Dept. of Rheumatology

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Conventional clinical and laboratory assessment

Conventional assessment plus ultrasonography

Arm Description

Outcomes

Primary Outcome Measures

Complete clinical Disease Activity Score (DAS) remission
Specifically, the primary endpoint will be the proportion of patients with all the following criteria met at the end of the study (at 24 months): DAS score < 1.6 at visits 11, 12 and 13 (after 16, 20 and 24 months) Absence of swollen joints at visits 11, 12 and 13 (after 16, 20 and 24 months) No radiological progression between visit 11 (16 months) and visit 13 (24 months)

Secondary Outcome Measures

Magnetic Resonance Imaging (MRI) of dominant hand
MRIs of dominant hand are scored according to the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for synovitis, bone marrow edema and erosions, and Haavardsholm tenosynovitis score, as well as a novel joint space narrowing score will be applied.
American College of Rheumatology (ACR) response
Proportion of patients with ACR20, ACR50, ACR70 and ACR90 response.
Remission
Various definitions of remission will be calculated, including DAS-remission, ACR-remission, Simplified Diseases Activity Index (SDAI) remission and Clinical Disease Activity Index (CDAI) remission
European League Against Rheumatism (EULAR) response
EULAR good, moderate and non-response
Work performance
Absenteeism (work time missed) Presenteeism (impairment at work / reduced on-the-job effectiveness) Work productivity loss (overall work impairment / absenteeism plus presenteeism) Activity Impairment
Conventional radiography
Radiographs of hands (posterior/anterior) and foot (anterior/posterior) will be taken at baseline, 3, 6, 12, 16 and 24 months. The modified Sharp van der Heijde Score (vdHSS) will be calculated, including an erosion score and a joint space narrowing score.
The RA Impact of Disease (RAID) score
The RAID includes seven domains with the following relative weights: pain (21%), functional disability (16%), fatigue (15%), emotional well-being (12%), sleep (12%), coping (12%) and physical well-being (12%).
EuroQol-5 Dimension (EQ-5D)
EQ-5D is a standardised instrument for use as a measure of health outcome.
Health Assessment Questionnaire (HAQ-PROMIS)
The HAQ-PROMIS is a questionnaire evaluating the physical function in patients with RA.
Medical Outcomes Study Short-Form 36-item (SF-36)
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.
Dual Energy X-ray Absorptiometry (DEXA) of spine and hip
Bone density measurements (DEXA hip and spine, both Z- and T-scores as well as bone mineral density) will be performed at baseline and after 12 and 24 months.
Disease Activity Score (DAS)
The DAS is a composite score that includes the Ritchie articular index (RAI), the 44- swollen joint counts (SJC-44), the Erythrocyte Sedimentation Rate (ESR) and a general health (GH) assessment on a Visual Analogue Scale (VAS). The DAS is calculated as follows: DAS = 0.54*sqrt(RAI) + 0.065*(SJC-44) + 0.33*Ln(ESR) + 0.0072*GH
Ultrasonography (synovitis)
36 joints and 2 tendons will be scored for both grey scale and power doppler synovitis on a 0-3 scale.
Magnetic Resonance Imaging (MRI) of dominant hand
MRIs of dominant hand are scored according to the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for synovitis, bone marrow edema and erosions, and Haavardsholm tenosynovitis score, as well as a novel joint space narrowing score will be applied.
American College of Rheumatology (ACR) response
Proportion of patients with ACR20, ACR50, ACR70 and ACR90 response.
European League Against Rheumatism (EULAR) response
EULAR good, moderate and non-response
Remission
Various definitions of remission will be calculated, including DAS-remission, ACR-remission, Simplified Diseases Activity Index (SDAI) remission and Clinical Disease Activity Index (CDAI) remission
Work performance
Absenteeism (work time missed) Presenteeism (impairment at work / reduced on-the-job effectiveness) Work productivity loss (overall work impairment / absenteeism plus presenteeism) Activity Impairment
Conventional radiography
Radiographs of hands (posterior/anterior) and foot (anterior/posterior) will be taken at baseline, 3, 6 and 12 months. The modified Sharp van der Heijde Score (vdHSS) will be calculated, including an erosion score and a joint space narrowing score.
The RA Impact of Disease (RAID) score
The RAID includes seven domains with the following relative weights: pain (21%), functional disability (16%), fatigue (15%), emotional well-being (12%), sleep (12%), coping (12%) and physical well-being (12%).
Health Assessment Questionnaire (HAQ-PROMIS)
The HAQ-PROMIS is a questionnaire evaluating the physical function in patients with RA.
Medical Outcomes Study Short-Form 36-item (SF-36)
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.
Dual Energy X-ray Absorptiometry (DEXA) of spine and hip
Bone density measurements (DEXA hip and spine, both Z- and T-scores as well as bone mineral density) will be performed at baseline and after 12 and 24 months.
Ultrasonography (synovitis)
36 joints and 2 tendons will be scored for both grey scale and power doppler synovitis on a 0-3 scale.
Disease Activity Score (DAS)
The DAS is a composite score that includes the Ritchie articular index (RAI), the 44- swollen joint counts (SJC-44), the Erythrocyte Sedimentation Rate (ESR) and a general health (GH) assessment on a Visual Analogue Scale (VAS). The DAS is calculated as follows: DAS = 0.54*sqrt(RAI) + 0.065*(SJC-44) + 0.33*Ln(ESR) + 0.0072*GH

Full Information

First Posted
September 16, 2010
Last Updated
April 15, 2015
Sponsor
Espen A. Haavardsholm
Collaborators
The Research Council of Norway, Smerud Medical Research International AS, Oslo University Hospital, Innovest, Abbott, UCB Nordic A/S, Pfizer, MSD Norway AS, Roche Pharma AG, The Norwegian Rheumatism Association
search

1. Study Identification

Unique Protocol Identification Number
NCT01205854
Brief Title
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Acronym
ARCTIC
Official Title
Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Espen A. Haavardsholm
Collaborators
The Research Council of Norway, Smerud Medical Research International AS, Oslo University Hospital, Innovest, Abbott, UCB Nordic A/S, Pfizer, MSD Norway AS, Roche Pharma AG, The Norwegian Rheumatism Association

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The ultimate goal of treatment in early rheumatoid arthritis (RA) is remission, i.e. an absence of signs and symptoms of the disease. However, the optimal way of reaching this goal is not known. Ultrasonography (US) is an imaging modality which application is rapidly growing. It has a number of advantages over other advanced imaging techniques such as magnetic resonance imaging (MRI), including low cost, good accessibility, and ability to scan many joints in a short period of time. However, the additional benefit of using this modality in terms of patient outcomes has not been demonstrated. Thus, clarification is needed if the use of US leads to better care for RA patients. This study will assess if the use of a treatment strategy incorporating information from ultrasonography assessment will allow for better outcomes of patients with RA, than a strategy based on clinical and laboratory assessments alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
Keywords
rheumatoid arthritis, ultrasonography, remission, imaging remission, tight control, treat to target

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
238 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conventional clinical and laboratory assessment
Arm Type
No Intervention
Arm Title
Conventional assessment plus ultrasonography
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Ultrasonography
Intervention Description
Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
Primary Outcome Measure Information:
Title
Complete clinical Disease Activity Score (DAS) remission
Description
Specifically, the primary endpoint will be the proportion of patients with all the following criteria met at the end of the study (at 24 months): DAS score < 1.6 at visits 11, 12 and 13 (after 16, 20 and 24 months) Absence of swollen joints at visits 11, 12 and 13 (after 16, 20 and 24 months) No radiological progression between visit 11 (16 months) and visit 13 (24 months)
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Magnetic Resonance Imaging (MRI) of dominant hand
Description
MRIs of dominant hand are scored according to the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for synovitis, bone marrow edema and erosions, and Haavardsholm tenosynovitis score, as well as a novel joint space narrowing score will be applied.
Time Frame
24 months
Title
American College of Rheumatology (ACR) response
Description
Proportion of patients with ACR20, ACR50, ACR70 and ACR90 response.
Time Frame
24 months
Title
Remission
Description
Various definitions of remission will be calculated, including DAS-remission, ACR-remission, Simplified Diseases Activity Index (SDAI) remission and Clinical Disease Activity Index (CDAI) remission
Time Frame
24 months
Title
European League Against Rheumatism (EULAR) response
Description
EULAR good, moderate and non-response
Time Frame
24 months
Title
Work performance
Description
Absenteeism (work time missed) Presenteeism (impairment at work / reduced on-the-job effectiveness) Work productivity loss (overall work impairment / absenteeism plus presenteeism) Activity Impairment
Time Frame
24 months
Title
Conventional radiography
Description
Radiographs of hands (posterior/anterior) and foot (anterior/posterior) will be taken at baseline, 3, 6, 12, 16 and 24 months. The modified Sharp van der Heijde Score (vdHSS) will be calculated, including an erosion score and a joint space narrowing score.
Time Frame
24 months
Title
The RA Impact of Disease (RAID) score
Description
The RAID includes seven domains with the following relative weights: pain (21%), functional disability (16%), fatigue (15%), emotional well-being (12%), sleep (12%), coping (12%) and physical well-being (12%).
Time Frame
24 months
Title
EuroQol-5 Dimension (EQ-5D)
Description
EQ-5D is a standardised instrument for use as a measure of health outcome.
Time Frame
24 months
Title
Health Assessment Questionnaire (HAQ-PROMIS)
Description
The HAQ-PROMIS is a questionnaire evaluating the physical function in patients with RA.
Time Frame
24 months
Title
Medical Outcomes Study Short-Form 36-item (SF-36)
Description
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.
Time Frame
24 months
Title
Dual Energy X-ray Absorptiometry (DEXA) of spine and hip
Description
Bone density measurements (DEXA hip and spine, both Z- and T-scores as well as bone mineral density) will be performed at baseline and after 12 and 24 months.
Time Frame
24 months
Title
Disease Activity Score (DAS)
Description
The DAS is a composite score that includes the Ritchie articular index (RAI), the 44- swollen joint counts (SJC-44), the Erythrocyte Sedimentation Rate (ESR) and a general health (GH) assessment on a Visual Analogue Scale (VAS). The DAS is calculated as follows: DAS = 0.54*sqrt(RAI) + 0.065*(SJC-44) + 0.33*Ln(ESR) + 0.0072*GH
Time Frame
24 months
Title
Ultrasonography (synovitis)
Description
36 joints and 2 tendons will be scored for both grey scale and power doppler synovitis on a 0-3 scale.
Time Frame
24 months
Title
Magnetic Resonance Imaging (MRI) of dominant hand
Description
MRIs of dominant hand are scored according to the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for synovitis, bone marrow edema and erosions, and Haavardsholm tenosynovitis score, as well as a novel joint space narrowing score will be applied.
Time Frame
12 months
Title
American College of Rheumatology (ACR) response
Description
Proportion of patients with ACR20, ACR50, ACR70 and ACR90 response.
Time Frame
12 months
Title
European League Against Rheumatism (EULAR) response
Description
EULAR good, moderate and non-response
Time Frame
12 months
Title
Remission
Description
Various definitions of remission will be calculated, including DAS-remission, ACR-remission, Simplified Diseases Activity Index (SDAI) remission and Clinical Disease Activity Index (CDAI) remission
Time Frame
12 months
Title
Work performance
Description
Absenteeism (work time missed) Presenteeism (impairment at work / reduced on-the-job effectiveness) Work productivity loss (overall work impairment / absenteeism plus presenteeism) Activity Impairment
Time Frame
12 months
Title
Conventional radiography
Description
Radiographs of hands (posterior/anterior) and foot (anterior/posterior) will be taken at baseline, 3, 6 and 12 months. The modified Sharp van der Heijde Score (vdHSS) will be calculated, including an erosion score and a joint space narrowing score.
Time Frame
12 months
Title
The RA Impact of Disease (RAID) score
Description
The RAID includes seven domains with the following relative weights: pain (21%), functional disability (16%), fatigue (15%), emotional well-being (12%), sleep (12%), coping (12%) and physical well-being (12%).
Time Frame
12 months
Title
Health Assessment Questionnaire (HAQ-PROMIS)
Description
The HAQ-PROMIS is a questionnaire evaluating the physical function in patients with RA.
Time Frame
12 months
Title
Medical Outcomes Study Short-Form 36-item (SF-36)
Description
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.
Time Frame
12 months
Title
Dual Energy X-ray Absorptiometry (DEXA) of spine and hip
Description
Bone density measurements (DEXA hip and spine, both Z- and T-scores as well as bone mineral density) will be performed at baseline and after 12 and 24 months.
Time Frame
12 months
Title
Ultrasonography (synovitis)
Description
36 joints and 2 tendons will be scored for both grey scale and power doppler synovitis on a 0-3 scale.
Time Frame
12 months
Title
Disease Activity Score (DAS)
Description
The DAS is a composite score that includes the Ritchie articular index (RAI), the 44- swollen joint counts (SJC-44), the Erythrocyte Sedimentation Rate (ESR) and a general health (GH) assessment on a Visual Analogue Scale (VAS). The DAS is calculated as follows: DAS = 0.54*sqrt(RAI) + 0.065*(SJC-44) + 0.33*Ln(ESR) + 0.0072*GH
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria (all): Male or non-pregnant, non-nursing female > 18 years of age and < 75 years of age Patients classified as having RA (according to new ACR/EULAR criteria) Disease duration less than 2 years (defined as time from 1st joint swelling) The treating rheumatologist decides the patient requires treatment with a Disease Modifying Anti-Rheumatic Drug (DMARD) The patient has taken no prior DMARD Patients able and willing to give written informed consent and comply with the requirements of the study protocol Exclusion Criteria (any): Abnormal renal function (serum creatinine > 142 µmol/L in female and > 168 µmol/L in male) Abnormal liver function, active or recent hepatitis, cirrhosis Major co-morbidities like severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease and/or severe respiratory diseases. Leukopenia and/or thrombocytopenia Inadequate birth control conception, pregnancy, and/or breastfeeding Indications of active tuberculosis Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tore K Kvien, MD, PhD
Organizational Affiliation
Diakonhjemmet Hospital AS
Official's Role
Study Director
Facility Information:
Facility Name
Martina Hansens Hospital AS
City
Sandvika
State/Province
Bærum
ZIP/Postal Code
1306
Country
Norway
Facility Name
Sykehuset Østfold HF, Dept. of Rheumatology
City
Moss
State/Province
Fredrikstad
ZIP/Postal Code
1603
Country
Norway
Facility Name
Helse Bergen HF, Haukeland University Hospital, Dept. of Rheumatology
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Vestre Viken HF, Dept. of Rheumatology
City
Drammen
ZIP/Postal Code
3004
Country
Norway
Facility Name
Haugesund Sanitetsforening Revmatismesykehus
City
Haugesund
ZIP/Postal Code
5504
Country
Norway
Facility Name
Sørlandet Sykehus HF, Dept. of Rheumatology
City
Kristiansand
ZIP/Postal Code
4604
Country
Norway
Facility Name
Revmatologene bendvold/Dovland
City
Kristiansand
ZIP/Postal Code
4611
Country
Norway
Facility Name
Diakonhjemmet Sykehus AS, Dept. of Rheumatology
City
Oslo
ZIP/Postal Code
0319
Country
Norway
Facility Name
Universitetssykehuset Nord-Norge HF, Dept. of Rheumatology
City
Tromsø
ZIP/Postal Code
9038
Country
Norway
Facility Name
St Olavs Hospital HF, Dept. of Rheumatology
City
Trondheim
ZIP/Postal Code
7006
Country
Norway
Facility Name
Helse Sunnmøre HF, Dept. of Rheumatology
City
Ålesund
ZIP/Postal Code
6026
Country
Norway

12. IPD Sharing Statement

Citations:
PubMed Identifier
31999341
Citation
Sundin U, Aga AB, Skare O, Nordberg LB, Uhlig T, Hammer HB, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology (Oxford). 2020 Sep 1;59(9):2550-2555. doi: 10.1093/rheumatology/kez674.
Results Reference
derived
PubMed Identifier
30053199
Citation
Paulshus Sundlisaeter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology (Oxford). 2018 Nov 1;57(11):2022-2031. doi: 10.1093/rheumatology/key202.
Results Reference
derived
PubMed Identifier
30001740
Citation
Jonsson MK, Hensvold AH, Hansson M, Aga AB, Sexton J, Mathsson-Alm L, Cornillet M, Serre G, Lillegraven S, Fevang BS, Catrina AI, Haavardsholm EA. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. Arthritis Res Ther. 2018 Jul 13;20(1):146. doi: 10.1186/s13075-018-1635-7.
Results Reference
derived
PubMed Identifier
29934373
Citation
Paulshus Sundlisaeter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. Ann Rheum Dis. 2018 Oct;77(10):1421-1425. doi: 10.1136/annrheumdis-2017-212830. Epub 2018 Jun 22.
Results Reference
derived
PubMed Identifier
29575737
Citation
Nordberg LB, Lillegraven S, Aga AB, Sexton J, Lie E, Hammer HB, Olsen IC, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA. The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen. Arthritis Rheumatol. 2018 Aug;70(8):1192-1199. doi: 10.1002/art.40494. Epub 2018 Jun 29.
Results Reference
derived
PubMed Identifier
28814431
Citation
Jonsson MK, Sundlisaeter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, Brokstad KA, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017 Dec;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695. Epub 2017 Aug 16.
Results Reference
derived
PubMed Identifier
28074154
Citation
Aga AB, Berner Hammer H, Christoffer Olsen I, Uhlig T, Kvien TK, van der Heijde D, Fremstad H, Madland TM, Lexberg AS, Haukeland H, Rodevand E, Hoili C, Stray H, Noraas AL, Widding Hansen IJ, Bakland G, Lillegraven S, Lie E, Haavardsholm EA. Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. RMD Open. 2016 Dec 16;2(2):e000325. doi: 10.1136/rmdopen-2016-000325. eCollection 2016.
Results Reference
derived
PubMed Identifier
27530741
Citation
Haavardsholm EA, Aga AB, Olsen IC, Lillegraven S, Hammer HB, Uhlig T, Fremstad H, Madland TM, Lexberg AS, Haukeland H, Rodevand E, Hoili C, Stray H, Noraas A, Hansen IJ, Bakland G, Nordberg LB, van der Heijde D, Kvien TK. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016 Aug 16;354:i4205. doi: 10.1136/bmj.i4205.
Results Reference
derived
PubMed Identifier
27094444
Citation
Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, Uhlig T, Jonsson MK, van der Heijde D, Kvien TK, Haavardsholm EA; and the ARCTIC working group. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naive patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis. 2017 Feb;76(2):341-345. doi: 10.1136/annrheumdis-2015-208873. Epub 2016 Apr 19.
Results Reference
derived
PubMed Identifier
26085490
Citation
Aga AB, Hammer HB, Olsen IC, Uhlig T, Kvien TK, van der Heijde D, Fremstad H, Madland TM, Lexberg AS, Haukeland H, Rodevand E, Hoili C, Stray H, Bendvold AN, Soldal DM, Bakland G, Lie E, Haavardsholm EA. First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach. Ann Rheum Dis. 2016 Aug;75(8):1444-51. doi: 10.1136/annrheumdis-2015-207572. Epub 2015 Jun 17.
Results Reference
derived

Learn more about this trial

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

We'll reach out to this number within 24 hrs